Co-Morbid Opioid Addiction and Chronic Pain

阿片类药物成瘾与慢性疼痛的共病 摘要 这个K23指导的以患者为导向的研究职业发展奖的主要目标是提供 博士临床健康心理学家艾米·瓦赫霍尔茨（Amy Wachholtz）接受了高级研究培训， 研究，并指导必要的经验，她成为一个独立的研究人员在发展 评估阿片类药物成瘾和合并症疼痛的创新治疗方法， （药物治疗和心理社会治疗）和新的（CBT和自我调节技术）。的 候选人提出一个研究和培训计划，以满足这一职业目标，包括：1）发展 关于阿片类药物成瘾和疼痛之间的心理和生理相互作用的知识，2） 增加她对成瘾的心理和药理治疗方法的了解，3） 建立心理社会治疗发展的技能，4）提高她对高级统计学的理解 技术，和5）建设在赠款写作和赠款管理的专业知识。Wachholtz博士将由 她的主要导师，Gerardo Gonzalez，医学博士，和两位共同导师，道格拉斯Ziedonis，医学博士，公共卫生硕士，和马丁 Cheatle博士Wachholtz博士将在共病疼痛和阿片类药物领域进行两项不同的研究。 成瘾第一项研究（疼痛反应性研究）是一项120名参与者的实验室研究; 90名使用阿片类药物 成瘾和慢性疼痛，以确定独特的生理，心理和行为反应， 在接受美沙酮阿片类药物维持治疗的阿片类药物成瘾者中诱发疼痛（30名参与者）; 接受丁丙诺啡阿片类药物维持治疗（30名参与者），有阿片类药物成瘾史，但 长期戒断阿片类药物（6个月以上）（30名参与者）和30名阿片类药物初治参与者。基于 第一项研究的结果，第二项研究（干预研究）将开发和试点测试30名受试者， 综合CBT +自我调节心理社会治疗，用于阿片类药物成瘾和疼痛的共病，以减少 物质使用，减轻疼痛，并降低对疼痛和痛苦的生理反应。结果将通知A 未来R 01应用于测试共病疼痛和阿片类药物成瘾的综合治疗。成功 这个K23奖的完成将推动Wachholtz博士进入职业生涯作为一个独立的研究人员与 专业知识进行临床研究试验，以改善对阿片类药物成瘾和疼痛的治疗。

Co-Morbid Opioid Addiction and Chronic Pain ABSTRACT The primary goal of this K23 – Mentored Patient-Oriented Research Career Development Award is to provide Dr. Amy Wachholtz, a clinical health psychologist, with the advanced research training, protected time for research, and mentored experiences necessary for her to become an independent researcher in developing and evaluating innovative treatments for opioid addiction and co-morbid pain that are integrative (pharmacotherapy and psychosocial treatment) and novel (CBT and Self-Regulation Techniques). The candidate proposes a program of research and training to meet this career goal including: 1) developing knowledge about the psychological and physiological interactions between opioid addiction and pain , 2) increasing her knowledge about psychological and pharmacological treatment approaches to addiction, 3) building skills in psycho-social treatment development, 4) enhancing her understanding of advanced statistical techniques, and 5) building expertise in grant writing and grant administration. Dr. Wachholtz will be guided by her primary mentor, Gerardo Gonzalez, MD, and two co-mentors, Douglas Ziedonis, MD, MPH, and Martin Cheatle, PhD. Dr. Wachholtz will conduct two distinct studies in the area of co-morbid pain and opioid addiction. The first study (Pain Reactivity Study) is a laboratory study of 120 participants; 90 with opioid addiction and chronic pain to identify the unique physiological, psychological, and behavioral responses to induced pain among those on methadone opioid maintenance treatment for opioid addiction (30 participants); on buprenorphine opioid maintenance treatment (30 participants), with an opioid addiction history but prolonged abstinence (6+ months) from opioids (30 participants), and 30 opioid naïve participants. Based on findings from the first study, the second study (Intervention Study) will develop and pilot test 30 subjects in an integrated CBT + Self-Regulation psycho-social treatment for co-morbid opioid addiction and pain to decrease substance use, reduce pain, and decrease physiological reactivity to pain and distress. Results will inform a future R01 application to test an integrated treatment for co-morbid pain and opioid addiction. Successful completion of this K23 award will advance Dr. Wachholtz into a career as an independent researcher with the expertise to conduct clinical research trials to improve treatment for co-morbid opioid addiction and pain.